Irish hospitals will be offered a €500 (US $561) incentive for each patient switched from brand-name Humira or Enbrel to a biosimilar option.
Irish hospitals will be offered a €500 (US $561) incentive for each patient switched from brand-name Humira or Enbrel to a biosimilar option.
The Irish Times reports that the incentives, which will be paid to hospitals rather than to individual prescribers, are part of an effort to switch half of Irish patients receiving these drugs to cost-saving options.
If successful, the approach could save approximately €50 million (US $56 million) in drug costs, and €8.7 million (US $9.7 million) of those savings would be put back into the national healthcare system.
Ireland is undertaking the program in response to low rates of switching to biosimilars, despite the availability of biosimilar options to these 2 high-cost therapies; since biosimilar etanercept became available, it has captured just 1.8% of the market for etanercept.
Ireland’s Medicines Management Program (MMP), a body that promotes cost-effective drug prescribing, began an evaluation process in early 2019 under which it reviewed the use of currently reimbursed anti—tumor necrosis factor (anti-TNF) therapies, which the MMP’s roadmap for prescribing best-value biologics noted represent the highest-expenditure category for Ireland’s reimbursement plan, comprising nearly one-third of drug spending.
Then, in May 2019, the MMP released its guide to best-value biologics for anti-TNFs. The guide recommends that prescribers use Samsung Bioepis’ Imraldi (which as an acquisition price of €623.46, or US $700, for a pack of 2 40-mg injections in prefilled syringes) in place of brand-name Humira (after rebate, €781.48, or US $878), or the citrate-free Amgevita, sold by Amgen (€662.83, or US $744) if needed.
In place of brand-name Enbrel (with an after-rebate acquisition cost of €358.29, or US $402, for a pack of 4 prefilled syringes with doses of 25 mg each), MMP recommends prescribing Samsung Bioepis’ Benpali (€354.53, or US $389). These recommendations apply to new start and to already-treated patients.
According to the MMP, acquisition costs, indications, formulation, product ranges (including pack sizes and strengths), administration devices, supply to the Irish market, and other relevant factors were considered in developing these recommendations.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.